CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Everolimus

Last Updated: March 8, 2013
Result type: Reports
Project Number: SR0315-000
Product Line: Common Drug Review

Generic Name: Everolimus

Brand Name: Afinitor

Manufacturer: Novartis Pharmaceuticals Canada Inc.

Indications: renal angiomyolipoma associated with tuberous sclerosis complex (TSC)

Submission Type: New

Project Status: Complete

Date Recommendation Issued: September 25, 2013

Recommendation Type: Do not list